Identifying germline mutations in BRCA1 and BRCA2 genes would benefit the carriers by taking risk-reducing interventions before they get a cancer, as well as providing valuable information on the therapeutic application of Poly (ADP-ribose) polymerase inhibitors after a cancer occurs (Fong et al., 2009; Domchek et al., 2010). The gene discussed is BRCA1; the disease is cancer.